×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 8, Track B: Clinical and Commercial Challenges of Emerging Therapies: Lessons Learned from Psychedelics and Cannabinoids
Session Chair(s)
Oxana Iliach, PhD
Senior Director Regulatory Strategy
Certara, Canada
Sabrina Ramkellawan
Chief Operating Officer
AxialBridge, Canada
This session will discuss challenges and opportunities for psychedelic and cannabinoids clinical development, regulatory strategies, intellectual property and commercialization.
Learning Objective : - Discuss the challenges and considerations for planning clinical trials with emerging therapies such as psychedelics and cannabinoids including how regulatory and clinical strategy impacts success of obtaining funding and early-stage investments
-
Identify challenges and review lessons learned from conducting clinical trials with psychedelics and cannabinoids
- Discuss Intellectual property and commercialization challenges for psychedelic and cannabinoid compounds
Speaker(s)
Clinical & Commercial Challenges of Emerging Therapies: Lessons Learned from Psychedelics and Cannabinoids
Sabrina Ramkellawan
AxialBridge, Canada
Chief Operating Officer
Clinical & Commercial Challenges of Emerging Therapies: Lessons Learned from Psychedelics and Cannabinoids
Kim McDonald-Taylor, MS, MSc
Clinical Research Association of Canada, Canada
Clinical Research Consultant
Regulatory Challenges and Considerations Including How to Design Effective Nonclinical and Clinical Program with Psychedelics and Cannabinoids
Ana Dukic, MPharm
Axialbridge, Canada
RA/QA
Commercial Challenges of Emerging Therapies: Intellectual property and Commercialization Challenges for Psychedelic and Cannabinoid Compounds
John Greiss, JD, RPh
Norton Rose Fulbright Canada, Canada
Senior Associate
Have an account?